Vectura inhaler wins first Latin America approval
Revolutionary inhaler technology from Vectura, whose delivery devices division is based in Cambridge UK, has made an important first breakthrough into Latin America.
Mexico’s Health Authority has granted marketing approval for AirFluSal Forspiro in 50-100 mg, 50-250 mg and 50-500 mg dosage forms. The products will be branded IrFlosol Forspiro in Mexico.
Airflusal Forspiro has already been launched in four European countries as well as in South Korea.
Chief executive Dr Chris Blackwell said the innovative new inhaler would benefit patients with asthma or chronic obstructive pulmonary disease (COPD).
He said the product’s safety, efficacy and equivalence have been proven in multiple clinical trials. Vectura initially developed the VR315 product and created the design of the innovative inhaler, before licensing the asset to Sandoz in 2006.
It was subsequently developed in collaboration with Vectura as AirFluSal Forspiro by Aeropharm GmbH in Germany, Sandoz’s global respiratory Center of Excellence. The intuitive-to-use design of the inhaler was awarded the Red Dot Product Design award in 2011, an internationally recognised quality seal awarded by the Design Zentrum Nordrhein Westfalen in Essen, Germany.
The Mexico approval is the latest in a string of global successes for the company with a burgeoning pipeline of therapies for the treatment of airways-related diseases. This growing market is estimated to be worth in excess of $46 billion worldwide.
Vectura has eight products marketed by partners and a portfolio of drugs in clinical development, a number of which have been licensed to major pharmaceutical companies.
Vectura has disclosed development collaborations and licence agreements with partners such as Novartis, Sandoz, Baxter, GlaxoSmithKline, UCB, Ablynx, Grifols and Tianjin KingYork Group Company Limited.